Summary

Oligonucleotides Market – Scope of Report
TMR’s report on the global oligonucleotides market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global oligonucleotides market for the period 2018–2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global oligonucleotides market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the oligonucleotides market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global oligonucleotides market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global oligonucleotides market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global oligonucleotides market.

The report delves into the competitive landscape of the global oligonucleotides market. Key players operating in the global oligonucleotides market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global oligonucleotides market profiled in this report.

Key Questions Answered in Global oligonucleotides Market Report
• What is the sales/revenue generated by oligonucleotides across all regions during the forecast period?
• What are the opportunities in the global oligonucleotides market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Oligonucleotides Market – Research Objectives and Research Approach
The comprehensive report on the global oligonucleotides market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global oligonucleotides market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global oligonucleotides market.

ページTOPに戻る

Table of Contents

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Oligonucleotides Market
4. Market Overview
    4.1. Introduction
        4.1.1. Segmentation Definition
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Oligonucleotides Market Analysis and Forecasts, 2020-2034
        4.4.1. Market Revenue Projections (US$ Bn)
5. Key Insights
    5.1. No. of Oligonucleotides being developed in world by Key Regions
    5.2. List of top Oligonucleotides products
    5.3. Pricing Analysis
    5.4. Go-to-Market Strategy
    5.5. Key Purchase Metrics for End-users
    5.6. PESTEL Analysis
    5.7. Key Industry Events
    5.8. Porter's Five Forces Analysis
    5.9. Regulatory Scenario by Key Countries/Regions
    5.10. Product/Brand Analysis
    5.11. Distributors Landscape
    5.12. Technological Advancements
    5.13. Fund Raise/Investment Scenario
    5.14. Recommendations and Analyst View for the Market
6. Global Oligonucleotides Market Analysis and Forecasts, By Type
    6.1. Introduction & Definition
    6.2. Key Findings / Developments
    6.3. Market Value Forecast By Type, 2020-2034
        6.3.1. Antisense Oligonucleotides
        6.3.2. DNA
        6.3.3. siRNA
        6.3.4. Others (CpG Oligonucleotides)
    6.4. Market Attractiveness By Type
7. Global Oligonucleotides Market Analysis and Forecasts, By Application
    7.1. Introduction & Definition
    7.2. Key Findings / Developments
    7.3. Market Value Forecast By Application, 2020-2034
        7.3.1. Molecular Biology
        7.3.2. Gene Therapy
        7.3.3. Drug Development
        7.3.4. Diagnostics
        7.3.5. Others (Nanotechnology, Research studies etc.)
    7.4. Market Attractiveness By Application
8. Global Oligonucleotides Market Analysis and Forecasts, By End-user
    8.1. Introduction & Definition
    8.2. Key Findings / Developments
    8.3. Market Value Forecast By End-user, 2020-2034
        8.3.1. Hospitals
        8.3.2. Pharma & Biopharma Companies
        8.3.3. Diagnostic Laboratories
        8.3.4. Biotechnology Companies
        8.3.5. CROs and CMOs
        8.3.6. Others (Academic Research Institutes, etc.)
    8.4. Market Attractiveness By End-user
9. Global Oligonucleotides Market Analysis and Forecasts, By Region
    9.1. Key Findings
    9.2. Market Value Forecast By Region
        9.2.1. North America
        9.2.2. Europe
        9.2.3. Asia Pacific
        9.2.4. Latin America
        9.2.5. Middle East & Africa
    9.3. Market Attractiveness By Country/Region
10. North America Oligonucleotides Market Analysis and Forecast
    10.1. Introduction
        10.1.1. Key Findings
    10.2. Market Value Forecast By Type, 2020-2034
        10.2.1. Antisense Oligonucleotides
        10.2.2. DNA
        10.2.3. siRNA
        10.2.4. Others (CpG Oligonucleotides)
    10.3. Market Value Forecast By Application, 2020-2034
        10.3.1. Molecular Biology
        10.3.2. Gene Therapy
        10.3.3. Drug Development
        10.3.4. Diagnostics
        10.3.5. Others (Nanotechnology, Research studies etc.)
    10.4. Market Value Forecast By End-user, 2020-2034
        10.4.1. Hospitals
        10.4.2. Pharma & Biopharma Companies
        10.4.3. Diagnostic Laboratories
        10.4.4. Biotechnology Companies
        10.4.5. CROs and CMOs
        10.4.6. Others (Academic Research Institutes, etc.)
    10.5. Market Value Forecast By Country, 2020-2034
        10.5.1. U.S.
        10.5.2. Canada
    10.6. Market Attractiveness Analysis
        10.6.1. By Type
        10.6.2. By Application
        10.6.3. By End-user
        10.6.4. By Country
11. Europe Oligonucleotides Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast By Type, 2020-2034
        11.2.1. Antisense Oligonucleotides
        11.2.2. DNA
        11.2.3. siRNA
        11.2.4. Others (CpG Oligonucleotides)
    11.3. Market Value Forecast By Application, 2020-2034
        11.3.1. Molecular Biology
        11.3.2. Gene Therapy
        11.3.3. Drug Development
        11.3.4. Diagnostics
        11.3.5. Others (Nanotechnology, Research studies etc.)
    11.4. Market Value Forecast By End-user, 2020-2034
        11.4.1. Hospitals
        11.4.2. Pharma & Biopharma Companies
        11.4.3. Diagnostic Laboratories
        11.4.4. Biotechnology Companies
        11.4.5. CROs and CMOs
        11.4.6. Others (Academic Research Institutes, etc.)
    11.5. Market Value Forecast By Country/Sub-region, 2020-2034
        11.5.1. Germany
        11.5.2. UK
        11.5.3. France
        11.5.4. Italy
        11.5.5. Spain
        11.5.6. Rest of Europe
    11.6. Market Attractiveness Analysis
        11.6.1. By Type
        11.6.2. By Application
        11.6.3. By End-user
        11.6.4. By Country/Sub-region
12. Asia Pacific Oligonucleotides Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast By Type, 2020-2034
        12.2.1. Antisense Oligonucleotides
        12.2.2. DNA
        12.2.3. siRNA
        12.2.4. Others (CpG Oligonucleotides)
    12.3. Market Value Forecast By Application, 2020-2034
        12.3.1. Molecular Biology
        12.3.2. Gene Therapy
        12.3.3. Drug Development
        12.3.4. Diagnostics
        12.3.5. Others (Nanotechnology, Research studies etc.)
    12.4. Market Value Forecast By End-user, 2020-2034
        12.4.1. Hospitals
        12.4.2. Pharma & Biopharma Companies
        12.4.3. Diagnostic Laboratories
        12.4.4. Biotechnology Companies
        12.4.5. CROs and CMOs
        12.4.6. Others (Academic Research Institutes, etc.)
    12.5. Market Value Forecast By Country/Sub-region, 2020-2034
        12.5.1. China
        12.5.2. India
        12.5.3. Japan
        12.5.4. Australia & New Zealand
        12.5.5. Rest of Asia Pacific
    12.6. Market Attractiveness Analysis
        12.6.1. By Type
        12.6.2. By Application
        12.6.3. By End-user
        12.6.4. By Country/Sub-region
13. Latin America Oligonucleotides Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast By Type, 2020-2034
        13.2.1. Antisense Oligonucleotides
        13.2.2. DNA
        13.2.3. siRNA
        13.2.4. Others (CpG Oligonucleotides)
    13.3. Market Value Forecast By Application, 2020-2034
        13.3.1. Molecular Biology
        13.3.2. Gene Therapy
        13.3.3. Drug Development
        13.3.4. Diagnostics
        13.3.5. Others (Nanotechnology, Research studies etc.)
    13.4. Market Value Forecast By End-user, 2020-2034
        13.4.1. Hospitals
        13.4.2. Pharma & Biopharma Companies
        13.4.3. Diagnostic Laboratories
        13.4.4. Biotechnology Companies
        13.4.5. CROs and CMOs
        13.4.6. Others (Academic Research Institutes, etc.)
    13.5. Market Value Forecast By Country/Sub-region, 2020-2034
        13.5.1. Brazil
        13.5.2. Mexico
        13.5.3. Rest of LATAM
    13.6. Market Attractiveness Analysis
        13.6.1. By Type
        13.6.2. By Application
        13.6.3. By End-user
        13.6.4. By Country/Sub-region
14. Middle East & Africa Oligonucleotides Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast By Type, 2020-2034
        14.2.1. Antisense Oligonucleotides
        14.2.2. DNA
        14.2.3. siRNA
        14.2.4. Others (CpG Oligonucleotides)
    14.3. Market Value Forecast By Application, 2020-2034
        14.3.1. Molecular Biology
        14.3.2. Gene Therapy
        14.3.3. Drug Development
        14.3.4. Diagnostics
        14.3.5. Others (Nanotechnology, Research studies etc.)
    14.4. Market Value Forecast By End-user, 2020-2034
        14.4.1. Hospitals
        14.4.2. Pharma & Biopharma Companies
        14.4.3. Diagnostic Laboratories
        14.4.4. Biotechnology Companies
        14.4.5. CROs and CMOs
        14.4.6. Others (Academic Research Institutes, etc.)
    14.5. Market Value Forecast By Country/Sub-region, 2020-2034
        14.5.1. South Africa
        14.5.2. GCC Countries
        14.5.3. Rest of MEA
    14.6. Market Attractiveness Analysis
        14.6.1. By Type
        14.6.2. By Application
        14.6.3. By End-user
        14.6.4. By Country/Sub-region
15. Competition Landscape
    15.1. Market Player - Competition Matrix (By Tier and Size of companies)
    15.2. Market Share Analysis By Company (2023)
    15.3. Company Profiles
        15.3.1. Agilent Technologies
            15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.1.2. Product Portfolio
            15.3.1.3. Financial Overview
            15.3.1.4. SWOT Analysis
            15.3.1.5. Strategic Overview
        15.3.2. Ajinomoto Bio-Pharma Services
            15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.2.2. Product Portfolio
            15.3.2.3. Financial Overview
            15.3.2.4. SWOT Analysis
            15.3.2.5. Strategic Overview
        15.3.3. CordenPharma
            15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.3.2. Product Portfolio
            15.3.3.3. Financial Overview
            15.3.3.4. SWOT Analysis
            15.3.3.5. Strategic Overview
        15.3.4. Creative Biolabs
            15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.4.2. Product Portfolio
            15.3.4.3. Financial Overview
            15.3.4.4. SWOT Analysis
            15.3.4.5. Strategic Overview
        15.3.5. Ella Biotech
            15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.5.2. Product Portfolio
            15.3.5.3. Financial Overview
            15.3.5.4. SWOT Analysis
            15.3.5.5. Strategic Overview
        15.3.6. Eurofins Genomics
            15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.6.2. Product Portfolio
            15.3.6.3. Financial Overview
            15.3.6.4. SWOT Analysis
            15.3.6.5. Strategic Overview
        15.3.7. Future synthesis
            15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.7.2. Product Portfolio
            15.3.7.3. Financial Overview
            15.3.7.4. SWOT Analysis
            15.3.7.5. Strategic Overview
        15.3.8. Integrated DNA Technologies
            15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.8.2. Product Portfolio
            15.3.8.3. Financial Overview
            15.3.8.4. SWOT Analysis
            15.3.8.5. Strategic Overview
        15.3.9. Kaneka Eurogentec
            15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.9.2. Product Portfolio
            15.3.9.3. Financial Overview
            15.3.9.4. SWOT Analysis
            15.3.9.5. Strategic Overview
        15.3.10. Thermo Fisher Scientific Inc.
            15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.10.2. Product Portfolio
            15.3.10.3. Financial Overview
            15.3.10.4. SWOT Analysis
            15.3.10.5. Strategic Overview
        15.3.11. Merck
            15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.11.2. Product Portfolio
            15.3.11.3. Financial Overview
            15.3.11.4. SWOT Analysis
            15.3.11.5. Strategic Overview
        15.3.12. Microsynth
            15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.12.2. Product Portfolio
            15.3.12.3. Financial Overview
            15.3.12.4. SWOT Analysis
            15.3.12.5. Strategic Overview
        15.3.13. Nitto Avecia
            15.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.13.2. Product Portfolio
            15.3.13.3. Financial Overview
            15.3.13.4. SWOT Analysis
            15.3.13.5. Strategic Overview